Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPX-351 (daunorubicin + cytarabine) (Jazz Pharmaceuticals plc, 041b4a)
- Development stage
- Phase 4
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CPX-351 (Vyxeos) is a liposomal formulation containing a fixed 5:1 molar ratio of cytarabine and daunorubicin. It is specifically designed to deliver these two synergistic chemotherapy agents to the bone marrow in a way that maintains the optimal ratio for killing leukemia cells while reducing systemic toxicity. Cytarabine acts as a pyrimidine analog that interferes with DNA synthesis, while daunorubicin is an anthracycline that intercalates into DNA and inhibits topoisomerase II. CPX-351 was developed by Celator Pharmaceuticals (now Jazz Pharmaceuticals) and is FDA-approved for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
- Brand names
- Vyxeos
- Other names
- daunorubicin and cytarabine liposomeliposomal cytarabine and daunorubicinliposomal daunorubicin and cytarabine
02
Targets
DNADNA polymerase familyTOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on CPX-351 (daunorubicin + cytarabine) (Jazz Pharmaceuticals plc, 041b4a).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPX-351 (daunorubicin + cytarabine) (Jazz Pharmaceuticals plc, 041b4a).